|
| Available: 0 |
| List Price:$62.95 |
|
|
| Edition: | 5th |
| Publisher: | Saunders, W. B. |
| ISBN: | 1-4557-5419-6 (1455754196) |
| ISBN-13: | 978-1-4557-5419-9 (9781455754199) |
| New Edition: | 0-323-60882-5 |
| Old Edition: | 0-7216-0359-9 |
| Format: | Examination Question |
| Binding: | Softcover |
| Copyright: | 2016 |
| Publish Date: | 03/15 |
| Weight: | 1.09 Lbs. |
| Pages: | 248 |
| Carton Quantity: | 32 |
| Subject Class: | N-O (Oncologic Nursing) |
| Remarks: | A New Edition of this Title is Available |
| Return Policy: | Returns accepted up to 10 months provided no other recalls or return restrictions apply. |
| Table Of Contents: |
View
|
| Contributing Authors: |
View
|
|
|
| |
| Discipline: | Nursing | | Subject Definition: | Oncologic Nursing-Examination Questions | | NLM Class: | WY 18.2 | | LC Class: | RC266 | | Abstract: | Get the most out of your OCN. Exam review with this helpful study tool! Corresponding to the chapters in The Core Curriculum for Oncology Nursing, 5th Edition, this definitive study guide endorsed by the Oncology Nursing Society covers the entire scope of practice for oncology nursing. It is based on the latest test blueprint for the OCN Exam, with more than 1,200 practice questions addressing all oncology topics, including the newest advances in cancer treatment and related nursing care. Prepare to succeed on your OCN Exam with this ONS-endorsed study resource! ... NEW! Revised and updated content reflects the latest CCN Examination test blueprint and The Core Curriculum for Oncology Nursing, 5th Edition. NEW emphasis on application-level questions helps you apply your knowledge more effectively. NEW! Updates on cancer treatment and related nursing care include the most current and accurate information, preparing you for the OCN Exam and for expert clinical practice. NEW! Emphasis on QSEN competencies is designed to reduce errors in oncology nursing practice with a focus on safety and evidence-based practice, including a Safety Alert icon and a High-Alert Medication icon for cancer chemotherapy drugs. |
|
|